Research Halted on Major Alzheimer's Drug

In the wake of another negative trial with the anti-amyloid drug bapineuzumab, Pfizer and Janssen said they were halting development of the product for mild to moderate Alzheimer's disease. All ongoing studies with the drug, a monoclonal antibody intended to break up beta amyloid protein plaques, will be discontinued, according to a statement released by Pfizer. This includes extension studies of previous randomized trials. The decision came after a placebo-controlled phase III trial led by...Full Story